If I’d invested £10,000 in AstraZeneca shares one year ago, here’s what I’d have now!

Dr James Fox takes a closer look at the biggest stock, by market cap, on the FTSE 100 and asked whether AstraZeneca shares can continue to outperform.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Couple working from home while daughter watches video on smartphone with headphones on

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE:AZN) shares are the crown jewel of the FTSE 100, very much in the way that Lloyds and its peers were in the 90s. The pharma and biotech giant is the index’s standout star over the past five years — it’s up an astonishing 120% over the period.

But if I’d invested £10,000 AstraZeneca a year ago, how would my investment be doing today? Well, unsurprisingly — given the five-year performance — very well. The stock is up 17%, meaning my £10,000 a year ago would be worth £11,700 today. I’d have also received around £200 in dividends.

However, I’m not an AstraZeneca shareholder. I was briefly over the past year, but I needed some capital and had to sell my holding. The big question is, what about now? Can AstraZeneca keep its bull run going?

Today, I’m focusing on prospects and valuation.


During the latter stages of the pandemic, Covid-related sales supported the company’s outperformance. In Q3 of 2022, for example, topline sales came in 3% ahead of Wall Street consensus estimates. Excluding Covid sales, it was a 2% miss.

But there’s broad optimism about the company moving forward, supported by a huge product pipeline and some positive developments, including Japan’s approval of three drugs for cancer and leukemia in late 2022 — this could be worth $10bn in sales over five to eight years — and recent positive results in lung cancer trials.

Tagrisso, the name given to the lung cancer drug, massively outperformed in phrase three testing. The results were “about twice as good as we expected“, the company noted.

But in 2023, we can expect revenue to be driven forward by Enhertu — a breast cancer drug. Researchers said this week that the HER2 antibody-drug conjugate could be used against other tumour types.

To compliment this, we can observe that AstraZeneca has one of the most exciting pipelines in the industry, with 178 projects in development right now. By comparison, Pfizer only has 101. Its main FTSE 100 counterpart, GSK, has 68.

However, it’s worth highlighting that its pipeline is dominated by label expansion projects for drugs that have already entered the market, as opposed to entirely new opportunities.


But all this doesn’t come cheap. The stock trades with a price-to-earnings ratio of 48 and a forward price-to-earnings of 25. Biopharma firms often trade at premiums as it’s a highly developmental and lucrative sector. However, it’s definitely possible to find cheaper biopharma stocks to invest in.

Nonetheless, I’m looking to purchase AstraZeneca once again. It’s still in a dip — possibly after some profit-taking following Q1 results — and this could be a good opportunity to buy in. The company has forecasted total revenue this year to increase by a low double-digit percentage and EPS in high-single to low-double-digits.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has positions in GSK. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

How to start earning passive income for life with just £3.40 a day

Dividends can be a tremendous and lucrative source of passive income, even when only investing a tiny sum each day.…

Read more »

Investing Articles

2 bargain FTSE 100 shares with dividend yields above 9%!

These FTSE 100 stocks look cheap, based on predicted earnings and dividends. Here's why I think they could be great…

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

2 top growth shares I’d buy for the second half of 2024!

Looking for the best growth shares to buy? These FTSE 250 and small-cap shares have significant share price potential, according…

Read more »

Investing For Beginners

How to try and build a £250k Stocks and Shares ISA from scratch, starting in 2024

With a regular savings plan and a smart investment strategy, it’s possible to build wealth within a Stocks and Shares…

Read more »

Investing Articles

I’m considering 3 top UK dividend stocks for my portfolio this July

Mark David Hartley is looking at adding a few dividend stocks to his portfolio this month. Will these three shares…

Read more »

Investing Articles

3 FTSE 100 shares I’d buy to create lasting passive income

Dividend stocks are a great way to build an additional income. Our writer details three FTSE 100 picks she’d love…

Read more »

Investing Articles

After falling 9% in 6 weeks, is this FTSE 100 stock now in bargain territory?

The BAE Systems share price hit a 52-week high on 3 June. Six weeks later, it’s down nearly 10%. Is…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

I love the look of Entain shares, potentially 47% undervalued

Many FTSE 100 companies have been on a tear in 2024, but with Entain shares down nearly 50%, I think…

Read more »